MedTrace Logo

Brain Death and Organ Donation in Tunisian Intensive Care Units

NCT06948669 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 104

Last updated 2025-04-29

No results posted yet for this study

Summary

The goal of this observational study was to identify factors associated with the progression to brain death in critically ill patients with severe brain injuries in Tunisian intensive care units (ICUs). The main questions it aimed to answer were:

What medical factors (e.g., type of brain injury, ICU stay duration) increased the likelihood of progressing to brain death in these patients?

What patient characteristics (e.g., age, comorbidities) influenced the risk of brain death?

What were the reasons behind low organ donation rates in Tunisia, including family refusal and hospital-level barriers?

Participants were:

Adults with severe coma (Glasgow Coma Scale ≤ 8) requiring mechanical ventilation in Tunisian ICUs.

Data were collected as part of routine medical care, including information about medical factors, patient characteristics, and family attitudes towards organ donation, without any additional interventions beyond standard care.

The study was conducted from November 2022 to November 2023 across three ICUs: Sahloul, Farhat Hached, and Mohamed Taher Maamouri Hospitals.

Conditions

  • Brain Injury
  • Coma
  • Organ Transplants

Sponsors & Collaborators

  • Faculty of Medicine, Sousse

    lead OTHER

Principal Investigators

  • Imed Chouchene, MD Professor · Intensive Care Unit University Hospital of Farhat Hached Sousse Tunis Faculty of Medicine of Sousse

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-11-01
Completion
2023-11-25

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06948669 on ClinicalTrials.gov